Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma

被引：19

作者：

Goldfarb, Jeremy Allan ^{[1
]}

Ferrarotto, Renata ^{[2
]}

Gross, Neil ^{[3
]}

Goepfert, Ryan ^{[3
]}

Debnam, James Matthew ^{[4
]}

Gunn, Brandon ^{[5
]}

Nagarajan, Priyadharsini ^{[6
]}

Esmaeli, Bita ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Plast Surg, Orbital Oncol & Ophthalm Plast Surg, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Med Oncol, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Neuroradiol, Houston, TX USA

[5] Univ Texas MD Anderson, Dept Radiat Oncol, Div Radiat Oncol, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA

来源：

BRITISH JOURNAL OF OPHTHALMOLOGY | 2023年 / 107卷 / 03期

关键词：

eye lids; neoplasia; orbit; pathology; treatment medical; PHASE-II; METASTASIS; CEMIPLIMAB; HEAD;

D O I：

10.1136/bjophthalmol-2021-319417

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose To report on the outcomes of immunotherapy in patients with locally advanced periorbital squamous cell carcinoma. Methods We performed a retrospective chart review of seven consecutive patients with locally advanced periorbital cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy. Treatments and therapeutic outcomes were reviewed. Results Of the seven patients, six were treated with cemiplimab, and one was treated with pembrolizumab. Five patients were treated with immunotherapy as neoadjuvant therapy before planned surgical resection; two patients received immunotherapy for treatment of advanced recurrent lesions deemed unresectable following multiple previous excisions and radiation therapy. In all seven patients, measurable clinical and/or radiologic response was observed. Conclusions Our findings support the emerging role of anti-PD-1 immunotherapy in the management of locally advanced periorbital cutaneous squamous cell carcinoma.

引用

页码：320 / 323

页数：4

共 50 条

[1] Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
Stern, Peter L.
Dalianis, Tina
VIRUSES-BASEL, 2021, 13 (07):
[2] Immune checkpoint inhibitors in sinonasal squamous cell carcinoma
Park, Jong Chul
Faquin, William C.
Durbeck, Julia
Faden, Daniel L.
ORAL ONCOLOGY, 2020, 109
[3] Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
Bossi, Paolo
Lorini, Luigi
DERMATOLOGY PRACTICAL & CONCEPTUAL, 2021, 11
[4] Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma
Chang, Hui-Chin
Gau, Shuo-Yan
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2025, 151 (02)
[5] Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma
Sun, Mengfei
Yang, Pengjie
Wang, Weisong
Yu, Yongjun
Yang, Dongdong
Ping, Yaodong
Zhu, Benben
AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (05): : 1981 - 1998
[6] Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
Baba, Yoshifumi
Nomoto, Daichi
Okadome, Kazuo
Ishimoto, Takatsugu
Iwatsuki, Masaaki
Miyamoto, Yuji
Yoshida, Naoya
Baba, Hideo
CANCER SCIENCE, 2020, 111 (09) : 3132 - 3141
[7] Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma
Parikh, Mamta
Bajwa, Poornima
SEMINARS IN NEPHROLOGY, 2020, 40 (01) : 76 - 85
[8] Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma
Patel, Roma
Chang, Anne Lynn S.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (04) : 477 - 482
[9] Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
Jiao, Ruidi
Luo, Hui
Xu, Wenbo
Ge, Hong
ONCOTARGETS AND THERAPY, 2019, 12 : 6023 - 6032
[10] Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
Jin, Zhao
Cao, Yanshuo
Lu, Zhihao
Liu, Chang
Shen, Lin
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137

← 1 2 3 4 5 →